MedTrace Logo

Impact of Oligonol to Cardiometabolic Risk and Muscular Health

NCT03788577 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2023-04-14

No results posted yet for this study

Summary

This project will mainly focus on Middle and old-aged adults, and examine whether Cardiovascular and metabolic risks can be reduced. In the meanwhile, this project will develop strategies for improving muscle loss , muscle strength decline, and the quality life of the elderly.

Conditions

  • Muscle Loss
  • Muscle Weakness
  • Quality of Life

Interventions

DIETARY_SUPPLEMENT

Oligonol intake

Major intervention of Oligonol component , as suggested Oligonol safe dose for adults is 200mg per day.

DIETARY_SUPPLEMENT

Placebo

Placebo

Sponsors & Collaborators

  • National Yang Ming Chiao Tung University

    lead OTHER

Principal Investigators

  • Liang-Kung Chen, MD.PhD. · Center for Healthy Longevity and Aging Sciences, National Yang Ming University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-04
Primary Completion
2020-04-01
Completion
2020-04-01

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03788577 on ClinicalTrials.gov